Targeting cancer with therapeutic antibodies: Solutions for every phase of mAb development


Although mAbs have been used in the treatment of cancer for more than 30 years, ongoing in the understanding of cancer biology and the emergence of next-generation sequencing technologies have accelerated the identification of molecular drivers of cancer and the search for antibody-based agents to block them.

This whitepaper identifies the key challenges faced at each stage of mAb development and provides guidance for streamlining pipeline progress of therapeutic mAb candidates, focusing specifically on the following:

  • Leveraging technology in the early stages to accelerate development while reducing risk
  • Scaling processes and production to match clinical and commercial demands
  • Integrating key regulatory considerations as a precursor to long-term success
  • Accelerating the start-to-finish workflow